Upper GI Tract
From the Journals
What explains poor adherence to eosinophilic esophagitis therapy?
Among patients with eosinophilic esophagitis, less than half complied with long-term medical or dietary therapy, according to a new study.
Flashback
Then and Now: A ‘lifetime’ of advancement in upper GI tract
GI & Hep News board member Dr. David Katzka reflects on the breathtaking progress in the upper GI tract field since 2007.
From the Journals
Baclofen shows limited role in GERD
The drug showed benefit in PPI refractory symptoms for patients with non-acid reflux.
From the Journals
New eosinophilic esophagitis severity score may guide treatment
The index, called I-SEE, includes symptoms, endoscopic findings, and histology and is meant to help steer clinicians to the best treatment...
Conference Coverage
Eosinophilic diseases often overlap, raising costs
Overlap was less common in eosinophilic esophagitis, but more common in eosinophilic gastritis/eosinophilic gastroenteritis.
Conference Coverage
H. pylori antibiotics briefly disrupt gut microbiome
Researchers compared antibiotic resistance following either levofloxacin quadruple therapy or bismuth quadruple therapy.
Conference Coverage
More evidence dementia not linked to PPI use in older people
Investigators assessed almost 19,000 older adults for use of PPI or H2RA medications and risk for incident dementia or cognitive decline over time...
News
FDA approves first drug for eosinophilic esophagitis
Dupilumab (Dupixent) is approved to treat eosinophilic esophagitis in adults and children aged 12 years and older weighing at least 40 kg.
From the Journals
Psychiatric illness associated with eosinophilic esophagitis
Eosinophilic esophagitis is associated with a high prevalence of psychiatric illnesses, according to a new study.
From the Journals
Vibrating wearable device may help night time GERD
The device appears to train patients to sleep on their left side with a resulting decrease in night time reflux symptoms.